Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Companies

Set Alert for Companies

ViiV In It For The Long Haul In HIV Market Battle With Gilead

The GSK-led joint venture has taken the lead in long-acting HIV treatment and prevention but has put back timelines on a key self-administered candidate.

Infectious Diseases Business Strategies

Gilead And AbbVie Are Not The Only Ones Re-Thinking CD47 Immunotherapies

CD47 was once seen as one of the hottest properties in immunotherapy, but multiple setbacks have tempered enthusiasm for targeting the ‘don’t eat me’ cell surface protein. I-Mab and Gilead are just two casualties.

Deals Clinical Trials

Achieve Life Sciences Believes It Has The New Chantix

Armed with an old drug and new data, the group is aiming to revitalize the smoking cessation market. 

Clinical Trials Neurology

China’s IPO Tightening Adds To Uncertainties Over Biotechs Going Public

China’s top securities regulator is slowing down the review of initial public offering applications across the board to “stabilize” the stock market. But event prior to the move, Chinese biotechs were operating already under a continuously tightening IPO environment.

China Financing

Ex-Novartis John Tsai Takes The Reins At Cardiovascular-Focused Forcefield Therapeutics

The ex-chief medical officer at Novartis is now CEO at the UK-based biotech, which he he told Scrip could have a ‘transformational’ therapy to protect patients after a heart attack.

Companies Leadership

Ionis Closer To First Wholly-Owned Drug Launch With Olezarsen Phase III Success

Ionis will seek US and EU approvals to treat familial chylomicronemia syndrome in the first half of 2024. Phase III data in the larger severe hypertriglyceridemia indication are due in late 2024 or early 2025.

Clinical Trials Rare Diseases

Biopharma’s Must-Know Q4 Catalysts

Cytokinetics has a lot riding on the upcoming Phase III readout for aficamten, and crunch time is coming for plenty of other groups, too. 

Clinical Trials Companies

Stock Watch: Exploring Biotech’s Route Through Bubble And Wilderness

Biotech has always been a volatile sector, and it is important for investors to recognize the phases its stocks go through. In particular, the journey through the post-bubble wilderness can be a protracted affair.

Stock Watch Financing

Novartis’s Lutathera To Be First Radiopharmaceutical In Frontline Use After Trial Success

The Swiss pharma giant is building momentum in radiopharmaceuticals by racking up positive pivotal trial data and overcoming manufacturing bottlenecks.

Clinical Trials Cancer

What Opdivo Has To Beat In Perioperative Lung Cancer

A positive showing by Bristol Myers Squibb’s checkpoint inhibitor Opdivo in non-small cell lung cancer could broaden its use, though much depends on the magnitude of the hit.

Clinical Trials Research & Development

Promising Early Results For AZ And Daiichi’s Dato-DXd In Breast Cancer – But How Soon Can They File?

Once again choosing their words carefully, the partners talk only of ‘plans’ to file as regulators will first have to clarify when overall survival data will be required for the new antibody-drug conjugate in breast cancer.

Cancer Clinical Trials

Genentech Joins Hunt For ‘Molecular Glue’ Drugs With Orionis

Genentech is broadening its stake in the protein degradation field, following BMS and Merck & Co into molecular glue drugs.

Commercial Companies

RayzeBio And Genentech Show Interest In Radiopharmaceuticals Continues To Grow

RayzeBio's IPO and Genentech's first buy-in into the field show a wave of next-generation companies hoping to expand the radiopharmaceutical field.

Cancer Clinical Trials

Taking On Obesity The Hard Way

Despite the astounding efficacy and commercial potential of incretins in obesity, many groups are trying different mechanistic approaches to the disease – if only to enable combinations. 

Clinical Trials Companies

GSK Reorganizes Around Key R&D Areas As Lepore Exits

The UK-based company has replaced its single head of research with four therapy area-focused leaders as it looks to further boost R&D productivity.

Executive Changes Leadership
See All
UsernamePublicRestriction

Register